High Hopes For Heidelberg Pharma With Huadong Onboard
Pact With Chinese Group Close To Completion
Executive Summary
CEO Jan Schmidt-Brand tells Scrip that with another reliable long-term investor on the team alongside major shareholder Dievini, Heidelberg is well positioned to advance its amanitin-targeted antibody-drug conjugate candidates.
You may also be interested in...
Asia Deal Watch: Astellas, GO Team Up On Targeted Cancer Therapy
Astellas subsidiary Xyphos will partner with GO to discover novel antibodies against two glycoprotein targets. SciNeuro picks up abandoned GSK programs in cardiovascular medicine for potential use in the neurodegeneration space.
Argenx Eyes Hat-Trick Of Successful Launches For Vyvgart After CHMP Thumbs-Up
Anant Murthy, general manager of Argenx Europe, tells Scrip that the commercial infrastructure is in place for Vyvgart to enjoy a strong launch for the rare neuromuscular disorder which will mirror those seen in the US and Japan.
GSK And Novartis Double Down On Neglected Disease R&D Spend
GSK will invest over $1bn over the next decade to develop medicines that combat malaria, neglected tropical diseases and antibiotic resistance, while Novartis is putting in $250m over the next five years.